Movetis NV

The US FDA's Gastrointestinal Drugs Advisory Committee vote supporting the relaunch of the irritable bowel syndrome therapy Zelnorm (tegaserod) is a milestone event in the Gottlieb-era at the agency

Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPO

Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions

Sofinnova Partners of France has closed its seventh venture capital fund dedicated to the life sciences having raised €240 million ($312 million). Sofinnova Capital VII's investment strategy focuses o